Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.